ABSTRACT
Pregnancy-associated atypical hemolytic uremic syndrome (P-aHUS) is a rare disease. There are only few reports in the literature, and most are in the puerperium period. It is a thrombotic microangiopathy (TMA) characterized for microangiopathic hemolytic anemia, thrombocytopenia, and renal dysfunction. We report the case of a pregnant patient at 26.3 gestation weeks, who developed clinical features of TMA, neurological alterations, and septic shock; then after fetus and placental delivery, no clinical improvement was observed; a diagnostic protocol was performed due to suspicion of P-aHUS, showing improvement after the plasma exchange sessions and eculizumab. We present here a brief review of the case since it is an entity that needs to be suspected during pregnancy when TMA features and requires an immediate diagnosis to provide timely treatment.
Subject(s)
Atypical Hemolytic Uremic Syndrome , Humans , Female , Pregnancy , Atypical Hemolytic Uremic Syndrome/therapy , Atypical Hemolytic Uremic Syndrome/diagnosis , Adult , Plasma Exchange , Antibodies, Monoclonal, Humanized/therapeutic use , Antibodies, Monoclonal, Humanized/administration & dosage , Pregnancy Complications, Hematologic/therapy , Pregnancy Complications, Hematologic/diagnosisABSTRACT
Five pentasaccharide glycosides, murucins 1-5 (1-5), were isolated from the roots of the arboreal species Ipomoea murucoides, and their structures were elucidated by spectroscopic and chemical methods. Compounds 1-5 were evaluated for cytotoxicity against a small panel of cancer cell lines.
